vaginally administered pegylated lif antagonist blocked embryo implantation and eliminated non-target effects on bone in mice阴道分娩进行聚乙二醇生活拮抗剂阻止胚胎植入和消除非目标效应在小鼠骨.pdfVIP

Vaginally Administered PEGylated LIF Antagonist Blocked Embryo Implantation and Eliminated Non- Target Effects on Bone in Mice 1 2 3 2 2 Ellen Menkhorst *, Jian-Guo Zhang , Natalie A. Sims , Phillip O. Morgan , Priscilla Soo , Ingrid J. 3 2 4,5 4 6 Poulton , Donald Metcalf , Estella Alexandrou , Melissa Gresle , Lois A. Salamonsen , Helmut 4,5 2 1 Butzkueven , Nicos A. Nicola , Evdokia Dimitriadis 1 Embryo Implantation, Prince Henry’s Institute, Clayton, Australia, 2 Cancer and Haematology, The Walter and Eliza Hall Institute, Parkville, Australia, 3 Bone, Joint and Cancer, St Vincent’s Institute of Medical Research, Melbourne, Australia, 4 Multiple Sclerosis, Howard Florey Institute, Melbourne, Australia, 5 Department of Medicine, The University of Melbourne, Parkville, Australia, 6 Endometrial Remodelling, Prince Henry’s Institute, Clayton, Australia Abstract Female-controlled contraception/HIV prevention is critical to address health issues associated with gender inequality. Therefore, a contraceptive which can be administered in tandem with a microbicide to inhibit sexually transmitted infections, is desirable. Uterine leukemia inhibitory factor (LIF) is obligatory for blastocyst implantation in mice and associated with infertility in women. We aimed to determine whether a PEGylated LIF inhibitor (PEGLA) was an effective contraceptive following vaginal delivery and to identify non-uterine targets of PEGLA in mice. Vaginally-applied 125I-PEGLA accumula